CA2392102A1 - Use of a buffer to prevent candida albicans infections on the skin - Google Patents

Use of a buffer to prevent candida albicans infections on the skin Download PDF

Info

Publication number
CA2392102A1
CA2392102A1 CA002392102A CA2392102A CA2392102A1 CA 2392102 A1 CA2392102 A1 CA 2392102A1 CA 002392102 A CA002392102 A CA 002392102A CA 2392102 A CA2392102 A CA 2392102A CA 2392102 A1 CA2392102 A1 CA 2392102A1
Authority
CA
Canada
Prior art keywords
skin
occlusive
article
buffering
mucous membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002392102A
Other languages
French (fr)
Inventor
Bo Runeman
Jan Faergemann
Olle Larko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Essity Hygiene and Health AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2392102A1 publication Critical patent/CA2392102A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/46Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present application relates to using an ingredient capable of buffering within the pH range 2.0 - 5.5, for preparing a skin-occlusive or mucous membrane-occlusive article for preventing skin irritations and lesions caused by Candida albicans. Examples of such articles are absorbent articles, such as diapers, pantyliners and sanitary napkins, wound dressings, such as bandages, surgical tapes and plasters, and finally gloves, prostheses and indwelling catheters.

Description

Use of a buffer to prevent Candida albicans infections on the skin.
The present application relates to using a substance capable of buffering within the pH range 2.0 - 5.5, for preparing a skin-occlusive or mucous membrane-occlusive article for preventing skin irritations and lesions caused by Candida albicans. Ex-amples of such articles are absorbent articles, such as diapers and sanitary napkins, wound dressings, such as bandages surgical tapes and plasters, gloves, prostheses and indwelling catheters.
Introduction Infections caused by Candida albicans may constitute a major problem in connec-tion with using skin-occlusive, mucous membrane-occlusive and absorbent articles such as diapers, pantyliners, sanitary napkins and wound dressings. Candida albi-cans has been found to correlate with severity of diaper dermatitis (Benjamin L, Pe-diatrician 1987, suppl. 1, p. 21 - 26). There are investigators that give C.
Albicans a primary causative role in some expressions of diaper dermatitis (Leyden J and Kligman AM, Arch. Dermatol. 1978, vol 114, p. 56 - 59).
pH appears to be a major source of confusion and contradiction in the context of Candida ecology. Candida carriage in vivo can occur readily over a broad range of pH. pH may be a factor of significance in the pathological status of C.
albicans in vivo, but it does not exert its influence by affecting growth of the fungus, i.e. the rate of increase of its biomass (Odds FC, Candida and Candidosis. A review and ,~25 bibliography. 2°d ed. 1988, Bailliere Tindall). Dimorphism, the ability of G albi-cans to exist in a blastospore and a filamentous form, is reported to be influenced by pH (Buffo et al., Mycopathologia, vol. 85 (1984), p. 21-30; Odds (1988), supra).
The blastospore form is favoured by slightly acidic pH and the filamentous form at neutral pH or above. Furthermore, it has been shown that microfilaments play an important role during pH-regulated morphological transition (Yokoyama et al., Mi-crobiology, vol. 140 ( 1994), p. 281-287). Clinical observations of diabetic patients, where a higher skin surface pH is possibly correlated to candidal intertrigo, have been reported (Yosipovitch et al., Diabetes Care, vol. 16 (1993), p. 560-563).
As already mentioned, there is often a risk for infections, skin irritations and lesions when covering the skin or mucous membranes with absorbent articles, wound S dressings, plasters, gloves, prostheses and like articles. WO 98/57677 and 126 both disclose that a neutral or a slightly alkaline pH in connection with using absorbent articles may lead to skin irritation and problems with odorous substances.
According to the documents these problems are caused by lipases and proteinases present on the skin and the problems can be overcome by decreasing the pH of the absorbent article. The documents do not give any particular information about problems caused by Candida or how to reduce the virulence of Candida albicans.
Summary of the invention Now it has turned out that the virulence capability of Candida albicans can be sub-stantially impaired by decreasing pH of a skin-occlusive or mucous membrane-occlusive article to a value within the range from 2.0 to 5.5. Thus a skin-occlusive or mucous membrane-occlusive article such as an absorbent article (a diaper, a sanitary napkin, a pantyliner or a wound dressing, such as a bandage), a plaster, a surgical tape, said article containing a pharmaceutically acceptable non-toxic and non-irritating substance capable of buffering within the pH range 2:0 - 5.5, is used to for preventing skin irritations and lesions caused by Candida albicans.
Detailed description of the invention Accordingly, the present invention relates to using an ingredient capable of buffer-ing within the pH range 2.0 - 5.5, for preparing a skin-occlusive article for prevent-ing skin irritations and lesions caused by Candida albicans. Any pharmaceutically acceptable, non-toxic and non-irritating ingredient capable of buffering within the specified range can be used. Examples of suitable buffering ingredients are superab-sorbent particles showing a level of neutralisation within the range of 20 -50 %, and pharmaceutically acceptable, non-toxic and non-irritating buffering solutions, such as organic salt buffering solutions, for example an acetate buffer or a citrate buffer. The buffering solution can be directly added to the skin-occlusive or mucous membrane-occlusive article. Alternatively, a pharmaceutically acceptable gel con-s taming the buffering solution can be added. Examples of suitable gels include gels normally used for pharmaceutical purposes, such as agarose.
An acid buffering substance according to the present invention is added to a skin-occlusive article. As disclosed herein, the terms "skin-occlusive article" or "mucous membrane-occlusive article" relates to an article, which is intended to cover the skin or mucous membranes of a person. A skin-occlusive article or mucous membrane-occlusive article according to the present invention can be an absorbent article, such as a diaper, a sanitary napkin, a pantyliner or a wound dressing, a surgical tape, a plaster. gloves, prostheses or indwelling catheters. It is not critical for the invention how the acid buffering substance is added, and accordingly it can be added to the skin-occlusive article in many different ways. Examples of suitable methods for adding the acid buffering substance to the skin occlusive article are administration of a solution containing the acid buffering substance, or administration of said sub-stance as a powder or gel. The administration can be carried out in connection with manufacturing said article or after said article has been manufactured.
As disclosed herein, the term "pharmaceutically acceptable antifungal agent"
relates to compounds normally used to treat Candida infections, such as imidazole deriva-tives, nystatin and ciclopirox olamine. These compounds are added to the skin-occlusive or mucous membrane-occlusive article in amounts corresponding to com-mon therapeutical doses.
The present invention will now be described with reference to the enclosed figures and tables, in which:

Figure 1 shows an example of a diaper to which an acid buffering substance can be added in accordance with the invention;
Figure 2 discloses the natural distribution of skin surface pH on volar forearms in 15 females. The observations are mean values of left and right arm;
Figure 3 presents a diagram showing pH development of patch sites before, during and after wearing a patch buffered with an acid buffering substance and a regular reference patch;
Table I presents results from visual assessment of skin reaction to Candida albicans infection; and Table II shows growth of Candida albicans 24 hours after inoculation.
The diaper 100 disclosed in figure 1 comprises a liquid-permeable outer layer 1, for example made of a fibre fabric or a perforated plastic film, a liquid-impermeable outer layer 2, for example made of a plastic film or a hydrophobic fibre fabric, and finally an absorbent body 3 enclosed between the outer layers 1, 2.
The diaper is intended to surround the lower part of the trunk of the wearer like a pair of absorbing pants. It is therefore designed with two end parts 4, 5 as well as a narrower crutch part 6 between the end parts, which when the diaper is used is in-tended to be arranged in the crutch of the wearer between the legs. In order to obtain the desired pant design, adhesive flaps 7 are arranged close to the rear waist edge 8.
Upon use, the adhesive flaps are fastened to the front part 5 of the diaper, close to the front waist edge 9, in order to hold the diaper together around the waist of the wearer.
Moreover, the diaper according to figure 1 comprises pretightened elastic means 10, which may consist of elastic strings, elastic threads, elastic foam or another suitable material. The elastic means 10 are, for the sake simplicity, shown in outstreched condition. However, as soon as the stretching ceases they contract and form elastic bands in the diaper.
The absorbent body 3 in the example shown in figure 1 is formed by two layers 11,12, an upper liquid-receiving layer 1 l and a lower layer 12 which spreads and distributes the liquid. The upper liquid-receiving layer must quickly be able to re-ceive a large amount of liquid within a short amount of time, i.e. have a higher in-stantaneous liquid absorption capability, but the lower storage and distribution layer 12 must have a high liquid distribution capability and be able to drain liquid out from the receiving layer 11 and distribute this liquid in the storage and distribution layer 12. The differences between the layers 11, 12 can be accomplished by density differences. A more compressed fibre structure distributes the liquid better than a corresponding fibre structure having a lower density. Such a low-density structure has a higher instantaneous liquid absorption capability and a lower distribution ca-pability due to its larger pore size. Different absorption capabilities can also be achieved by using different fibre structures having different characteristics.
Thus chemically produced cellulose fluff pulp shows better distribution characteristics compared to, for instance, mechanically or chemi-thermomechanically produced pulp, such as chemi-thermomechanical pulp (CTMP). A fibre structure containing chemically stiffened cellurose=fibres shows a higher instantaneous liquid absorption ability but a lower distribution ability compared to conventional chemical pulp.
Other materials suitable as receiving layers 11 can be a wadding of natural fibres or a fluffy nonwoven material.
A partially neutralised superabsorbent is admixed in the upper liquid-receiving layer 11 of the absorbent body 3. This superabsorbent act as a acid buffering substance in accordance with the present invention.
A conventional superabsorbent is admixed in the lower liquid storage and distribu-tion layer 12 of the absorbent body. It is advantageous to put a conventional super-absorbent in the lower liquid storage layer 12, because a conventional superabsorb-ent has a higher total absorption capacity compared to a partially neutralised and pH-regulating superabsorbent.
Naturally, the invention also comprises other embodiments of the absorption body.
The absorbent body may contain both partially neutralised superabsorbents and conventional superabsorbents, and both the superabsorbents can be equally distrib-uted in both the upper and lower absorbent layers. Moreover, except for cellulose fluff pulp it is possible to only include one kind of superabsorbent material.
In that case, the superabsorbent material also acts as a pH-regulating substance in accor-dance with the present invention.
Experimental work A study was carried out in order to determine whether different environmental pH
affects Candida infections on skin. Fifteen female, healthy volunteers between and 63 years of age (average 44.5 years) participated. The following routine proce-dures and materials were used:
The experimental patches were made of common diaper materials and punched out as circular disks with a diameter of 70 mm. The outer side of polyethylene and the inner side (that will be placed towards the skin) of nonwoven polypropylene were glued together with a 10 mm edge around the inner circular core of 50 mm diameter.
The inner core consisted of approximately 0.85 g cellulose pulp and approximately 0.15 g of superabsorbent polymer (IM 7100 and E 127/97, Clairant GmbH, DE).
The superabsorbent polymer was a polyacrylic acid, which was adjusted to either pH
4.5 or 6Ø It acts as a strong buffering system. 104 cells per ml C. albicans were sus-pended in a physiological saline solution. 7 ml of this solution was added to each patch, 15 minutes before they were attached to the forearms.

Skin surface pH was measured with a Courage+Khazaka PH900, Mettler-Toledo flat electrode 304. Every morning and afternoon the instrument was calibrated at pH
4.0 and 7Ø The instrument accuracy is 0.1 units. A few drops of deionized water was added to the electrode before measurement and the average of three values was recorded.
The C. albicans strain used was type H29, kindly provided by Professor Lars Edebo, Department of Microbiology, Sahlgrenska University Hospital, Goteborg, SE. Cells were grown on Sabouraud's glucose agar at 37°C for 24 hours before use.
A modification of the Williamson-Kligman scrub technique was used for assess-ment of the resident skin microflora and the added C. albicans. A stainless steel ring with an internal diameter of 2.6 cm and covering a skin area of 5.5 cm2 was used.
One millimetre of sterile 0.075 M phosphate buffer (pH 7.9) containing 0.1%
Triton X-100 was poured into the ring, and the skin was gently rubbed with a blunt sterile glass rod for one minute and the fluid was removed with a Pasteur pipette (Faerge-mann J. Mapping the Fungi of the Skin. Handbook of Non-invasive Methods and the Skin, chapter 10.2, CRC Press, 1995). Serial dilutions were performed in PBS
and samples from the dilutions were plated out. Plates were incubated at 37°C and read after 48h.
The paired t test was used to test for statistical significance between pH
differences, differences in number of Candida organisms. The differences in observed skin 1e-sions were tested by a sign test.
At the start of the trial, skin microflora was determined with the scrub test.
All sub-jects had coagulase-negative Staphylococci (range 170-25000 colony-forming units (cfu)). Two of the subjects had Diphteroid sp (range 50 -2400 cfu). Four subjects had Bacillus sp (range 10-1200 cfu). One subject had S. aureus on one arm (10 cfu).

The amounts are given in colony-forming units per 5.5 cm2 skin. No growth of C.
albicans was found in any subject before the trial.
The skin surface pH of the 15 volunteers was measured at the start and varied be-tween 4.5 and 6Ø The mean value was 5.2. The results are shown in figure 2.
Patches preloaded with a Candida suspension ( 104 cells/ml) were taped to the fore-arms of the volunteers. The patches had two different pH-values and were randomly placed on either left or right arm. The patches were worn under strict occlusion for 24 hours. The patches were removed, and after approximately 2 minutes pH
values of the skin was measured. When the patches were removed after 24 hours of occlu-sion the pH was 5.1 +/- 0.18 and 5.7 +/-0.29 (mean +/- SD) at the two respective sites. The difference is statistically significant at p<0.0001. The skin was visually examined and was sampled to determine the number of cfu of Candida in an area of 5.5 cm2. The summarised results are shown in table II. No statistically significant difference (P=0.64) was found between the "acidic" site and the reference site.
Growth was found on both arms in 13 subjects. In one subject growth was found only on the "acidic" site, and in one subject only on the reference site.
After 48 hours, the pH measurements as well as the Candida sampling were re-peated. The results of the pH~measurements are disclosed in figure 3. The results of the Candida samplings after 48 hours, i.e. 24 hours after the patches had been re-moved and the lesions had become visually evident, show that 9 subjects had no growth at all of C. albicans. Three subjects showed low numbers (10-130 cfu) and one subject had an increased growth since the day before (1400 and 4300 cfu on re-spective arms). Two subjects were missing on this occasion, and accordingly no mi-crobial data could be obtained.
The skin lesions were visually assessed. No reaction = 0; faint reaction = l;
evident reaction = 2; strong reaction = 3. The reading was blinded and the patch type un-known to the assessor. The skin reactions were also recorded on photographs.
This visual assessment of skin reactions gave a very clear result. The acidic site had less severe reactions than the reference site in all 14 subjects that reacted. The sign test shows a statistically significant difference at p<0.001 for difference in reaction at the two sites. The detailed result is presented in table I.
Consequently, the pH-induced differences turned out not to be due to inhibited growth of Candida albicans. They are probably due to a pH influence of the viru-fence capacity of the fungus and/or an improvement of the host's defence ability.

Claims (7)

Claims
1. Use of a pharmaceutically acceptable, non-toxic and non-irritating ingredient ca-pable of buffering within the pH range 2.0 - 5.5, for preparing a skin-occlusive article or a mucous membrane-occlusive article for preventing skin irritations and lesions caused by Candida albicans.
2. Use of a pharmaceutically acceptable, non-toxic and non-irritating ingredient ca-pable of buffering within the pH range 2.0 - 5.5, together with a pharmaceutically acceptable antifungal agent such as an imidazole derivative, nystatin and ciclopirox olamine, for preparing a skin-occlusive article or a mucous membrane-occlusive ar-ticle for preventing skin irritations and lesions caused by Candida albicans.
3. Use according to claim 1 or claim 2, characterised in that the pharmaceutically acceptable, non-toxic and non-irritating buffering ingredient is a partially neutral-ised superabsorbent.
4. Use according to claim 1 or claim 2, characterised in that the pharmaceutically acceptable non-toxic and non-irritating buffering ingredient is an organic acid salt buffering solution.
5. Use according to anyone of claims 1 - 4 for preparing a skin-occlusive or mucous membrane-occlusive article, which is an absorbent article such as a diaper, a sani-tary napkin, or a pantyliner.
6. Use according to anyone of claims 1 - 4 for preparing a skin-occlusive or mucous membrane-occlusive article which is a wound dressing, a plaster, a surgical tape, or a like article.
7. Use according to anyone of claims 1 - 4 for preparing a skin-occlusive article or a mucous membrane-occlusive article, which is a glove, a prosthesis, or an in-dwelling catheter.
CA002392102A 1999-12-02 2000-11-06 Use of a buffer to prevent candida albicans infections on the skin Abandoned CA2392102A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9904387-9 1999-12-02
SE9904387A SE521431C2 (en) 1999-12-02 1999-12-02 Use of a pH buffering substance to prevent skin infections caused by Candida Albicans
PCT/SE2000/002165 WO2001039582A1 (en) 1999-12-02 2000-11-06 Use of a buffer to prevent candida albicans infections on the skin

Publications (1)

Publication Number Publication Date
CA2392102A1 true CA2392102A1 (en) 2001-06-07

Family

ID=20417954

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002392102A Abandoned CA2392102A1 (en) 1999-12-02 2000-11-06 Use of a buffer to prevent candida albicans infections on the skin

Country Status (13)

Country Link
EP (1) EP1233746A1 (en)
JP (1) JP2003515544A (en)
KR (1) KR20020060249A (en)
AU (1) AU778633B2 (en)
BR (1) BR0016005A (en)
CA (1) CA2392102A1 (en)
CO (1) CO5251413A1 (en)
MX (1) MXPA02005211A (en)
PL (1) PL355410A1 (en)
RU (1) RU2002117294A (en)
SE (1) SE521431C2 (en)
SK (1) SK7882002A3 (en)
WO (1) WO2001039582A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630152B2 (en) 1999-04-07 2003-10-07 Shen Wei (Usa), Inc. Aloe vera glove and manufacturing method
US6274154B1 (en) 1999-04-07 2001-08-14 Belle L Chou Aloe Vera glove and manufacturing method
EP1354586A1 (en) * 2002-04-20 2003-10-22 Aventis Pharma Deutschland GmbH The use of hydroxpyridone-derivatives in wound healing
US20030204893A1 (en) * 2002-05-02 2003-11-06 Chou Belle L. Elastomeric flexible article and manufacturing method
US9757285B2 (en) 2011-03-07 2017-09-12 Edgewell Personal Care Brands, Llc Absorbent article including a buffer composition
DE102011106046A1 (en) 2011-06-30 2013-01-03 Paul Hartmann Ag Wound Care Product

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794034A (en) * 1973-02-27 1974-02-26 J Jones Odor reductant body waste pad
PH23760A (en) * 1985-05-15 1989-11-03 Procter & Gamble Disposable absorbent articles
US4842593A (en) * 1987-10-09 1989-06-27 The Procter & Gamble Company Disposable absorbent articles for incontinent individuals
AU6044094A (en) * 1994-01-17 1995-08-01 Carlo Alfredo Graziani Napkin with buffer substance
SE511838C2 (en) * 1997-06-17 1999-12-06 Sca Hygiene Prod Ab Reduction of undesirable side effects when using absorbent articles by means of pH control
JP2001520188A (en) * 1997-10-22 2001-10-30 ポニカウ,ジェンス Methods and substances for treating and preventing inflammation of mucosal tissue
EP1061964B2 (en) * 1998-03-12 2009-10-28 The Procter & Gamble Company Proton donating actives in absorbent articles

Also Published As

Publication number Publication date
KR20020060249A (en) 2002-07-16
JP2003515544A (en) 2003-05-07
CO5251413A1 (en) 2003-02-28
RU2002117294A (en) 2004-01-27
SE521431C2 (en) 2003-11-04
PL355410A1 (en) 2004-04-19
SE9904387L (en) 2001-06-03
BR0016005A (en) 2002-07-30
SK7882002A3 (en) 2002-12-03
AU1906301A (en) 2001-06-12
EP1233746A1 (en) 2002-08-28
WO2001039582A1 (en) 2001-06-07
MXPA02005211A (en) 2002-12-09
SE9904387D0 (en) 1999-12-02
AU778633B2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
CN104906620B (en) A kind of hydrogel antibacterial gauze dressing and preparation method thereof
US20100151032A1 (en) Silver and Zinc Containing Body Care Agent
EP1791574B1 (en) Absorbent articles comprising a bodily exudate modifying agent and a film-forming skin care formulation
EP1185242B1 (en) An anti-microbial body care product
EP3305335A1 (en) Multifunctional compound skin or wound dressing as regenerative skin substitute
CA2313858A1 (en) Microporous films comprising flocked fibers
US20060062854A1 (en) Hydrogel having anti-microbial properties
KR20010085581A (en) Absorbent Article Which Maintains or Improves Skin Health
EP2209502B1 (en) Personal-care articles having self-assembling peptides
AU2007330862A1 (en) Antibacterial sheet and absorbent article
US7867510B2 (en) Material having antimicrobial activity when wet
CN103768647B (en) A kind of Chinese medicine health-care absorbent commodity
US20090010994A1 (en) Wound Dressing Comprising an Anti-Inflammatory Pain-Killing Agent and a Complex of Silver Ion and a Transitional Element of Group IV of the Periodic System of Elements
MXPA02000879A (en) Absorbent article which maintains skin temperature when wet.
EP3441054B1 (en) Device for the treatment of vaginal fungal infection
EP1465674B1 (en) Absorbent article comprising a yucca extract
WO2017019503A1 (en) Wound care products comprising alexidine
AU778633B2 (en) Use of a buffer to prevent candida albicans infections on the skin
US6559353B1 (en) Treated disposable articles for reducing skin breakdown
AU778161B2 (en) Hop acids used to inhibit staphylococcus aureus
US20090076474A1 (en) Absorbent articles comprising an aglycone derivable from an iridoid glycoside
JP2004255165A (en) Absorbent article
CN1359306A (en) Absorbent articles of personal hygiene with therapeutic effect
JP2017108910A (en) Body fluid absorbent article
CN118356525A (en) Liquid band-aid containing 5-aminolevulinic acid

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead